Omiya, Japan

Katsuo Hatayama

This inventor holds 38 USPTO granted patents, plus 7 CIPO patents, primarily in Chemical Compounds. Top assignees: Taisho Pharmaceutical Co., Ltd., Chinese Academy of Medical Sciences. Active years: 1978-1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Katsuo Hatayama. Retrieved from https://idiyas.com/inventor/katsuo-hatayama

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

 

Average Co-Inventor Count = 5.1

ph-index = 10

Forward Citations = 296(Granted Patents)


Location History:

  • Omiya, JA (1978)
  • Ohmiya, JP (1985 - 1994)
  • Omiya, JP (1984 - 1995)
  • Saitama, JP (1994 - 1996)
  • Tokyo, JP (1995 - 1998)

Company Filing History:


Years Active: 1978-1998

Loading Chart...
Loading Chart...
Areas of Expertise:
Quinoline Derivatives
Steroid Derivatives
Thiazoline Derivatives
Heterocyclic Compounds
Erythromycin Derivatives
Sulfonanilide Compounds
Carbazole Compounds
Dihydropyridine Derivatives
Vincaminic Acid Derivatives
Aminoalkylthiazole Derivatives
Chalcone Derivatives
Epoxysuccinamic Acid Derivatives
38 patents (USPTO):Explore Patents

Title: The Innovations of Katsuo Hatayama: A Pioneer in Gastrointestinal Research

Introduction

Katsuo Hatayama, based in Omiya, Japan, has made significant contributions to the field of gastrointestinal medicine through his innovative research and prolific patent portfolio. With a remarkable total of 38 patents, he stands out as an influential inventor in his domain.

Latest Patents

Among his latest innovations, Hatayama's patents include Quinolinecarboxylic acid derivatives and a heterocyclic compound known as Endo-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl) 1-isopropyl-2(1H)-quinolone-3-carboxylate. This compound represents a breakthrough in activating serotonin 4 receptors, leading to advancements in the treatment of various gastrointestinal conditions. His work has shown promise in alleviating issues such as heartburn, anorexia, bowel pain, and abdominal distension, which can arise from chronic gastritis or postoperative gastroparesis. Furthermore, it offers potential solutions for gastro-esophageal reflux, intestinal pseudo-obstruction, and constipation.

Career Highlights

Throughout his career, Katsuo Hatayama has been associated with prestigious organizations such as Taisho Pharmaceutical Co., Ltd. and the Institute of Materia Medica of the Chinese Academy of Medical Sciences. His expertise and dedication to research have positioned him as a leading figure in the pharmaceutical industry, particularly in the development of novel treatments for gastrointestinal disorders.

Collaborations

Hatayama has collaborated with prominent figures in the field, including Yutaka Kawashima and Sadakazu Yokomori. These partnerships have enhanced his research capabilities and contributed to the advancement of innovative solutions in gastrointestinal health.

Conclusion

Katsuo Hatayama's work exemplifies the spirit of innovation and dedication to improving human health. His extensive patent portfolio and collaborative efforts with esteemed colleagues in the industry underscore his role as a pioneer in developing effective treatments for gastrointestinal conditions, making him a noteworthy inventor in the scientific community.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…